Patents Represented by Attorney, Agent or Law Firm Curtis C. Panzer
  • Patent number: 7763659
    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner.
    Type: Grant
    Filed: March 1, 2007
    Date of Patent: July 27, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Barbara Hanney, Yuntae Kim, Michael R. Krout, Robert S. Meissner, Helen J. Mitchell, Jeffrey Musselman, James J. Perkins, Jiabing Wang
  • Patent number: 7705035
    Abstract: The invention is directed to indoline amide derivatives of formula I as EP4 receptor ligands, antagonists or agonists, useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis, cancer and glaucoma. Pharmaceutical compositions and methods of use are also included.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: April 27, 2010
    Assignee: Merck Frosst Canada Ltd.
    Inventors: Michael Boyd, John Colucci
  • Patent number: 7696217
    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: April 13, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: William P. Dankulich, Mildred L. Kaufman, Robert S. Meissner, Helen J. Mitchell
  • Patent number: 7687541
    Abstract: The invention encompasses the novel compounds of Formula (I) and Formula (II), which are prodrugs that convert in vivo to diaryl-2-(5H)-furanones useful in the treatment of cyclooxygenase-2 mediated diseases. These prodrugs are far more soluble in aqueous media than the active agents into which they convert, in vivo. As such compounds of Formula (I) and (II) are advantageous for, among other things intravenous administration. The invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula (I) and Formula (II).
    Type: Grant
    Filed: October 18, 2004
    Date of Patent: March 30, 2010
    Assignee: Merck & Co., Inc.
    Inventors: Jeannie M. Arruda, Benito Munoz, Brian A. Stearns
  • Patent number: 7629367
    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: December 8, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Barbara Hanney, Yuntae Kim, Michael R. Krout, Robert S. Meissner, Helen J. Mitchell, Jeffrey Musselman, James J. Perkins, Jiabing Wang
  • Patent number: 7625919
    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient.
    Type: Grant
    Filed: August 14, 2006
    Date of Patent: December 1, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Jiabing Wang, Carol A. McVean
  • Patent number: 7625920
    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
    Type: Grant
    Filed: November 18, 2008
    Date of Patent: December 1, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Robert S. Meissner, James J. Perkins
  • Patent number: 7622501
    Abstract: The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H)-furanones useful in the treatment of cyclooxygenase-2 mediated diseases, Formula (I). The invention also encompasses certain pharmaceutical compositions and methods for treating cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula 1. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic cardiovascular events.
    Type: Grant
    Filed: January 25, 2005
    Date of Patent: November 24, 2009
    Assignee: Merck Frosst Canada & Co.
    Inventors: Claude Dufresne, Carl Berthelette, Lianhai Li, Daniel Guay, Michel Gallant, Patrick Lacombe, Renee Aspiotis, Zhaoyin Wang, Claudio F. Sturino
  • Patent number: 7622592
    Abstract: Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient.
    Type: Grant
    Filed: October 28, 2003
    Date of Patent: November 24, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Yuntae Kim, Barbara Hanney, Mark E. Duggan, Keith L. Spencer
  • Patent number: 7622502
    Abstract: The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treating cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic cardiovascular events.
    Type: Grant
    Filed: January 25, 2005
    Date of Patent: November 24, 2009
    Assignee: Merck Frosst Canada & Co.
    Inventors: Carl Berthelette, Lianhai Li, Christian Beaulieu, Zhaoyin Wang, Claudio F. Sturino
  • Patent number: 7605152
    Abstract: Compounds of structural formula I as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue.
    Type: Grant
    Filed: January 10, 2003
    Date of Patent: October 20, 2009
    Assignee: Merck & Co., Inc.
    Inventors: William P. Dankulich, Robert S. Meissner, Helen J. Mitchell, James J. Perkins
  • Patent number: 7482359
    Abstract: Compounds of structural Formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination
    Type: Grant
    Filed: August 19, 2005
    Date of Patent: January 27, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Jiabing Wang, Joshua Close
  • Patent number: 7482357
    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: January 27, 2009
    Assignee: Merck & Co., Inc.
    Inventors: William P. Dankulich, Mildred L. Kaufman, Robert S. Meissner, Helen J. Mitchell
  • Patent number: 7482345
    Abstract: Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: January 27, 2009
    Inventors: Meng-Hsin Chen, James B. Doherty, Robert Tynebor
  • Patent number: 7446110
    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner.
    Type: Grant
    Filed: September 2, 2004
    Date of Patent: November 4, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Mildred L. Kaufman, Robert S. Meissner, Helen J. Mitchell
  • Patent number: 7442716
    Abstract: The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.
    Type: Grant
    Filed: November 23, 2005
    Date of Patent: October 28, 2008
    Assignee: Merck Frosst Canada Ltd.
    Inventors: Anh Chau, Bernard Cote, Yves Ducharme, Richard Frenette, Richard Friesen, Marc Gagnon, Andre Giroux, Evelyn Martins, Hongping Yu, Tom Wu
  • Patent number: 7429666
    Abstract: The present invention provides novel compounds of Formula I which are antagonists of the C5a receptor. Compounds of the present invention are useful for the treatment of various C5a-mediated diseases and disorders; accordingly the present invention provides a method for the treatment of C5a-mediated diseases using the novel compounds described herein, as well as pharmaceutical compositions containing them.
    Type: Grant
    Filed: February 8, 2005
    Date of Patent: September 30, 2008
    Assignee: Merck Frosst Canada Ltd.
    Inventors: Nicholas Lachance, Patrick Roy, Yves Leblanc
  • Patent number: 7410977
    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
    Type: Grant
    Filed: April 22, 2005
    Date of Patent: August 12, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Robert S. Meissner, James J. Perkins
  • Patent number: 7411073
    Abstract: The present invention encompasses compounds of Formula (I) or pharmaceutically acceptable salts or hydrates thereof, which are useful as novel non-steroidal selective glucocorticoid receptor modulators for treating a variety of autoimmune and inflammatory diseases or conditions, and possess advantages over steroidal glucocorticoid ligands with respect to undesireable side-effects, efficacy, toxicity and/or metabolism. Pharmaceutical compositions and methods of use are also included.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: August 12, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Amjad Ali, Richard Beresis, Steven L. Colletti, Donald W. Graham, James R. Tata, Christopher F. Thompson
  • Patent number: 7402577
    Abstract: Compounds of structural formula as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: July 22, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Jiabing Wang, Mark E. Duggan, David B. Whitman